NUVL

NUVL

USD

Nuvalent Inc. Class A Common Stock

$92.690-1.560 (-1.655%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$94.250

Máximo

$95.225

Mínimo

$92.075

Volumen

0.28M

Fundamentos de la Empresa

Capitalización de Mercado

6.7B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.46M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $55.535Actual $92.690Máximo $104.9

Noticias Relacionadas

PR Newswire

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Ver más
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Analyst Upgrades

UBS Maintains Buy on Nuvalent, Raises Price Target to $132

UBS analyst David Dai maintains Nuvalent with a Buy and raises the price target from $114 to $132.

Ver más
UBS Maintains Buy on Nuvalent, Raises Price Target to $132
PR Newswire

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

Ver más
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

Piper Sandler analyst Kelsey Goodwin maintains Nuvalent with a Overweight and raises the price target from $112 to $128.

Ver más
Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.